Log in
Lost password
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Shares  >  Nasdaq  >  Halozyme Therapeutics, Inc.    HALO

News SummaryMost relevantAll newsSector news 

Halozyme Therapeutics, Inc. : Halozyme to Host First Quarter 2012 Financial Results Conference Call

04/30/2012 | 04:20pm US/Eastern

SAN DIEGO, April 30, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the first quarter 2012 on Monday, May 7, 2012 at 4:30 p.m. ET/1:30 p.m. PT. Gregory I. Frost, President and Chief Executive Officer, will lead the call. On the same date post-market, Halozyme will release financial results for the first quarter 2012.

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

The call will be webcast live through the "Investors" section of Halozyme's corporate website and a recording will be made available following the close of the call. To access the webcast, please log on to www.halozyme.com approximately fifteen minutes prior to the call to register, download, and install any necessary audio software. For those without access to the Internet, the live call may be accessed by phone by calling (877) 407-8037 (domestic callers) or (201) 689-8037 (international callers). A telephone replay will be available shortly after the call by dialing (877) 660-6853 (domestic callers) or (201) 612-7415 (international callers) using account number 367 and replay ID number 393124.

About Halozyme
Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, that increase the absorption and dispersion of biologics. Halozyme's pipeline addresses therapeutic areas, such as diabetes, oncology and dermatology that have significant unmet medical need. The Company markets HYLENEX® recombinant (hyaluronidase human injection) and has partnerships with Roche, Baxter, ViroPharma and Intrexon. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at www.halozyme.com.

Media/Investor Contact:
Anne Erickson
Executive Director
Halozyme Therapeutics

SOURCE Halozyme Therapeutics, Inc.

React to this article
08/25 HALOZYME THERAPEUTICS : Appoints Michael J. Labarre As Chief Scientific Officer
08/25 HALOZYME THERAPEUTICS : names new chief scientific officer
08/24 HALOZYME THERAPEUTICS : Appoints Michael J. Labarre As Chief Scientific Officer
08/12 HALOZYME THERAPEUTICS : Appoints Jeffrey W. Henderson To Board
08/12 HALOZYME THERAPEUTICS : UCSF To Study Halozyme PEGPH20 In Pancreatic Cancer Pati..
08/10 HALOZYME THERAPEUTICS : beats 2Q profit forecasts
08/10 HALOZYME THERAPEUTICS : Management's Discussion and Analysis of Financial Condit..
08/10 HALOZYME THERAPEUTICS : Results of Operations and Financial Condition (form 8-K)
08/06 HALOZYME THERAPEUTICS : UCSF To Study Halozyme PEGPH20 In Pancreatic Cancer Pati..
08/06 HALOZYME THERAPEUTICS : Schedules Second Quarter 2015 Financial Results Conferen..